JP2009503097A - 酢酸プレドニゾロンの経口懸濁液 - Google Patents
酢酸プレドニゾロンの経口懸濁液 Download PDFInfo
- Publication number
- JP2009503097A JP2009503097A JP2008525163A JP2008525163A JP2009503097A JP 2009503097 A JP2009503097 A JP 2009503097A JP 2008525163 A JP2008525163 A JP 2008525163A JP 2008525163 A JP2008525163 A JP 2008525163A JP 2009503097 A JP2009503097 A JP 2009503097A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- prednisolone acetate
- prednisolone
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 title claims abstract description 48
- 229960002800 prednisolone acetate Drugs 0.000 title claims abstract description 48
- 229940100692 oral suspension Drugs 0.000 title abstract description 5
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims abstract description 23
- 229960005205 prednisolone Drugs 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 11
- 239000002562 thickening agent Substances 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 239000002245 particle Substances 0.000 claims description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- 229920002125 Sokalan® Polymers 0.000 claims description 13
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 12
- 229960001631 carbomer Drugs 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 6
- 230000001953 sensory effect Effects 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 230000007480 spreading Effects 0.000 claims description 4
- 238000003892 spreading Methods 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 3
- 229940067596 butylparaben Drugs 0.000 claims description 3
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 229940044519 poloxamer 188 Drugs 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 206010027654 Allergic conditions Diseases 0.000 claims description 2
- 208000027932 Collagen disease Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 208000030172 endocrine system disease Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 230000000873 masking effect Effects 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 239000004376 Sucralose Substances 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims 1
- 235000019408 sucralose Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 46
- 238000009472 formulation Methods 0.000 abstract description 34
- 239000000725 suspension Substances 0.000 description 24
- 239000003981 vehicle Substances 0.000 description 15
- 239000003826 tablet Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940124274 edetate disodium Drugs 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 239000008135 aqueous vehicle Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000007971 pharmaceutical suspension Substances 0.000 description 3
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- -1 malitol Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940068285 prednisolone 15 mg Drugs 0.000 description 1
- 229940102618 prednisolone 5 mg Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70537005P | 2005-08-04 | 2005-08-04 | |
| PCT/US2006/030140 WO2007019184A2 (en) | 2005-08-04 | 2006-08-03 | Oral suspension of prednisolone acetate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012236009A Division JP2013014634A (ja) | 2005-08-04 | 2012-10-25 | 酢酸プレドニゾロンの経口懸濁液 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009503097A true JP2009503097A (ja) | 2009-01-29 |
| JP2009503097A5 JP2009503097A5 (enExample) | 2009-09-17 |
Family
ID=37727875
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525163A Pending JP2009503097A (ja) | 2005-08-04 | 2006-08-03 | 酢酸プレドニゾロンの経口懸濁液 |
| JP2012236009A Abandoned JP2013014634A (ja) | 2005-08-04 | 2012-10-25 | 酢酸プレドニゾロンの経口懸濁液 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012236009A Abandoned JP2013014634A (ja) | 2005-08-04 | 2012-10-25 | 酢酸プレドニゾロンの経口懸濁液 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7799331B2 (enExample) |
| EP (2) | EP1909798A4 (enExample) |
| JP (2) | JP2009503097A (enExample) |
| KR (1) | KR20080044245A (enExample) |
| CN (1) | CN101247786A (enExample) |
| AU (1) | AU2006278620B2 (enExample) |
| CA (1) | CA2616112A1 (enExample) |
| IL (1) | IL189257A0 (enExample) |
| NZ (1) | NZ566117A (enExample) |
| WO (1) | WO2007019184A2 (enExample) |
| ZA (1) | ZA200800926B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019514975A (ja) * | 2016-05-06 | 2019-06-06 | ハーロウ・ヘルス・インコーポレイテッドＨａｒｒｏｗ Ｈｅａｌｔｈ， Ｉｎｃ． | 薬学的眼病用組成物およびそれを製造するための方法 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7799331B2 (en) | 2005-08-04 | 2010-09-21 | Taro Pharmaceutical North America, Inc. | Oral suspension of prednisolone acetate |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| WO2007117605A2 (en) * | 2006-04-06 | 2007-10-18 | Taro Pharmaceuticals North America, Inc. | Novel spill-resistant formulations comprising hydrocolloidal polymers |
| CN101888829A (zh) * | 2007-10-09 | 2010-11-17 | 诺瓦提斯公司 | 缬沙坦的药物制剂 |
| US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US20090123551A1 (en) * | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Gastrointestinal delivery systems |
| US20090143343A1 (en) * | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| KR101245604B1 (ko) | 2007-11-13 | 2013-03-21 | 메리테이지 파마, 인크. | 코르티코스테로이드 조성물 |
| US20090264392A1 (en) * | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
| LT2328553T (lt) * | 2008-08-20 | 2020-09-10 | The Regents Of The University Of California | Kortikosteroidai, skirti virškinimo trakto uždegiminių ligų gydymui |
| WO2010144865A2 (en) * | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| EP3509572A4 (en) * | 2016-09-08 | 2020-05-13 | Synergistic Therapeutics, LLC | TOPICAL FORMULATION FOR HAIR GROWTH |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002523475A (ja) * | 1998-09-02 | 2002-07-30 | アラーガン・セイルズ・インコーポレイテッド | 防腐したシクロデキストリン含有組成物 |
| WO2004082659A1 (en) * | 2003-03-17 | 2004-09-30 | Baxter International Inc. | Method for preparing small particles |
| US20050020551A1 (en) * | 2003-06-19 | 2005-01-27 | Bodor Nicholas S. | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application |
| JP2007533697A (ja) * | 2004-04-22 | 2007-11-22 | デュオコート エービー | グルココルチコイド救急治療用の医薬組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4265823A (en) * | 1979-01-04 | 1981-05-05 | Robert E. Kosinski | Aurothiosteroids |
| US4448774A (en) * | 1982-12-22 | 1984-05-15 | Fisons Corporation | Steroid formulation |
| US5145675A (en) * | 1986-03-31 | 1992-09-08 | Advanced Polymer Systems, Inc. | Two step method for preparation of controlled release formulations |
| US5525605A (en) * | 1992-07-30 | 1996-06-11 | Tokyo Tanabe Company Limited | Remedy for inflammatory intestinal diseases |
| IL108366A (en) * | 1993-03-11 | 1999-11-30 | Taro Vit Ind Ltd | Semi-solid pharmaceutical compounds and a device for their use |
| US5881926A (en) * | 1993-03-11 | 1999-03-16 | Taro Pharmaceutical Industries, Ltd. | Pharmaceutical compositions in semisolid form and a device for administration thereof |
| US20030203976A1 (en) * | 1993-07-19 | 2003-10-30 | William L. Hunter | Anti-angiogenic compositions and methods of use |
| US5480914A (en) | 1994-05-06 | 1996-01-02 | Allergan, Inc. | Nonaqueous thixotropic drug delivery suspensions and methods of their use |
| US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| US5763449A (en) * | 1996-08-07 | 1998-06-09 | Ascent Pediatrics, Inc. | Pleasant-tasting aqueous liquid composition of a bitter-tasting drug |
| US6071523A (en) * | 1998-06-03 | 2000-06-06 | Taro Pharmaceuticals Industries, Ltd. | Spill resistant pharmaceutical compositions in semi-solid form |
| EP1370226A2 (en) * | 2001-01-24 | 2003-12-17 | Oraceutical LLC | Topical oral care compositions |
| KR100824491B1 (ko) | 2001-10-05 | 2008-04-22 | 콤비네이토릭스, 인코포레이티드 | 면역염증 질환의 치료를 위한 조합 |
| US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
| KR20040080439A (ko) | 2001-12-12 | 2004-09-18 | 파마시아 코포레이션 | 에폭시-스테로이드성 알도스테론 수용체 길항제에 의한안구 질환의 치료 방법 |
| AU2003238221A1 (en) | 2002-06-17 | 2003-12-31 | Taro Pharmaceuticals U.S.A, Inc. | Ibuprofen suspension |
| CA2550811C (en) * | 2003-12-24 | 2012-05-01 | Jane Hirsh | Temperature-stable formulations, and methods of development thereof |
| US6969706B1 (en) * | 2004-05-12 | 2005-11-29 | Allergan, Inc. | Preserved pharmaceutical compositions comprising cyclodextrins |
| US7799331B2 (en) * | 2005-08-04 | 2010-09-21 | Taro Pharmaceutical North America, Inc. | Oral suspension of prednisolone acetate |
-
2006
- 2006-07-13 US US11/457,197 patent/US7799331B2/en active Active
- 2006-08-03 CA CA002616112A patent/CA2616112A1/en not_active Abandoned
- 2006-08-03 CN CNA2006800290686A patent/CN101247786A/zh active Pending
- 2006-08-03 NZ NZ566117A patent/NZ566117A/en unknown
- 2006-08-03 AU AU2006278620A patent/AU2006278620B2/en not_active Ceased
- 2006-08-03 KR KR1020087003972A patent/KR20080044245A/ko not_active Abandoned
- 2006-08-03 JP JP2008525163A patent/JP2009503097A/ja active Pending
- 2006-08-03 EP EP06789228A patent/EP1909798A4/en not_active Withdrawn
- 2006-08-03 EP EP13169273.3A patent/EP2630951A1/en not_active Withdrawn
- 2006-08-03 WO PCT/US2006/030140 patent/WO2007019184A2/en not_active Ceased
-
2008
- 2008-01-29 ZA ZA2008/00926A patent/ZA200800926B/en unknown
- 2008-02-04 IL IL189257A patent/IL189257A0/en unknown
-
2010
- 2010-08-27 US US12/870,144 patent/US8206727B2/en active Active
-
2012
- 2012-05-30 US US13/483,273 patent/US8461139B2/en not_active Expired - Fee Related
- 2012-10-25 JP JP2012236009A patent/JP2013014634A/ja not_active Abandoned
-
2013
- 2013-02-01 US US13/756,731 patent/US20130143853A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002523475A (ja) * | 1998-09-02 | 2002-07-30 | アラーガン・セイルズ・インコーポレイテッド | 防腐したシクロデキストリン含有組成物 |
| WO2004082659A1 (en) * | 2003-03-17 | 2004-09-30 | Baxter International Inc. | Method for preparing small particles |
| US20050020551A1 (en) * | 2003-06-19 | 2005-01-27 | Bodor Nicholas S. | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application |
| JP2007533697A (ja) * | 2004-04-22 | 2007-11-22 | デュオコート エービー | グルココルチコイド救急治療用の医薬組成物 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019514975A (ja) * | 2016-05-06 | 2019-06-06 | ハーロウ・ヘルス・インコーポレイテッドＨａｒｒｏｗ Ｈｅａｌｔｈ， Ｉｎｃ． | 薬学的眼病用組成物およびそれを製造するための方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2630951A1 (en) | 2013-08-28 |
| NZ566117A (en) | 2011-06-30 |
| AU2006278620A1 (en) | 2007-02-15 |
| KR20080044245A (ko) | 2008-05-20 |
| CN101247786A (zh) | 2008-08-20 |
| CA2616112A1 (en) | 2007-02-15 |
| US8461139B2 (en) | 2013-06-11 |
| US20070031459A1 (en) | 2007-02-08 |
| AU2006278620B2 (en) | 2012-02-02 |
| EP1909798A4 (en) | 2010-10-27 |
| ZA200800926B (en) | 2012-04-24 |
| US20100324007A1 (en) | 2010-12-23 |
| US7799331B2 (en) | 2010-09-21 |
| IL189257A0 (en) | 2008-08-07 |
| EP1909798A2 (en) | 2008-04-16 |
| JP2013014634A (ja) | 2013-01-24 |
| US20130143853A1 (en) | 2013-06-06 |
| WO2007019184A3 (en) | 2007-09-20 |
| US20120238534A1 (en) | 2012-09-20 |
| WO2007019184A2 (en) | 2007-02-15 |
| US8206727B2 (en) | 2012-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013014634A (ja) | 酢酸プレドニゾロンの経口懸濁液 | |
| EP3160444B1 (en) | A pharmaceutical oil-in-water nano-emulsion | |
| EP3843704B1 (en) | Emulsion formulations of multikinase inhibitors | |
| CN104902875B (zh) | 四环素局部制剂、其制备及用途 | |
| JP6092629B2 (ja) | リファキシミン使用準備済懸濁液 | |
| US20070077286A1 (en) | Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle | |
| ES2750246T3 (es) | Formulaciones liquidas orales de aprepitant | |
| WO2013024373A1 (en) | Pharmaceutical composition comprising cefuroxime | |
| JP2021523202A (ja) | 経口溶液製剤 | |
| CN101106995B (zh) | 在非水极性溶剂中增加溶解度的10-羟基喜树碱类化合物的药物制剂 | |
| WO2024180339A1 (en) | Liquid formulation comprising trilostane | |
| WO2024215214A1 (en) | Liquid composition of phosphodiesterase type 5 (pde-5) inhibitors, a method of preparation thereof and the use thereof for the treatment of erectile dysfunctions | |
| KR20250048301A (ko) | 아비라테론 아세테이트의 경구 제형 및 이의 제조방법 | |
| JPWO2002064114A1 (ja) | 新規眼科用組成物 | |
| Sushma et al. | Available online through |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090803 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090803 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120625 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120924 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121025 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130121 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130422 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130430 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130520 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130729 |